Drug Trials News for September 2013

to-BBB Presents Clinical Data on Lead Product 2B3-10, a Potential New Treatment Option for Patients with Brain Cancer

A novel drug for patients with brain cancer, 2B3-101, has shown preliminary positive results. The Dutch biotech to-BBB has developed 2B3-101 and initiated a clinical trial to investigate this new treatment. The Phase I safety results will be presented at the European Cancer Congress 2013 in Amsterdam at the end of September.
29 September, 2013

Zealand informs that data presented on Lyxumia® support known complementary effects of this diabetes medicine in combination with basal insulin

A sub-analysis of results from the GetGoal-L study shows that Lyxumia® added to basal insulin lowered blood sugar (HbA1c) especially when fasting glucose was controlled
24 September, 2013

CHAMPIX® (varenicline) is Effective and Well Tolerated Compared With Placebo in Patients With a History of Major Depressive Disorder (MDD)

Findings from a published double-blind, placebo-controlled, randomised clinical trial designed to assess the efficacy and safety of varenicline compared with placebo in patients with a history of MDD*
19 September, 2013

Almac and Queen’s University, Belfast announce £13 million investment in Cancer Research

Significant milestone achieved in clinical development of ground breaking new cancer drug, ALM201and academic-industrial partnership to create new drug discovery unit
12 September, 2013

Drug Trials News for September 2013

Drug Trials News Archive

to-BBB Presents Clinical Data on Lead Product 2B3-10, a Potential New Treatment Option for Patients with Brain Cancer to-BBB Presents Clinical Data on Lead Product 2B3-10, a Potential New Treatment Option for Patients with Brain Cancer

Zealand informs that data presented on Lyxumia® support known complementary effects of this diabetes medicine in combination with basal insulin Zealand informs that data presented on Lyxumia® support known complementary effects of this diabetes medicine in combination with basal insulin

CHAMPIX® (varenicline) is Effective and Well Tolerated Compared With Placebo in Patients With a History of Major Depressive Disorder (MDD) CHAMPIX® (varenicline) is Effective and Well Tolerated Compared With Placebo in Patients With a History of Major Depressive Disorder (MDD)

Almac and Queen’s University, Belfast announce £13 million investment in Cancer Research Almac and Queen’s University, Belfast announce £13 million investment in Cancer Research

to-BBB Presents Clinical Data on Lead Product 2B3-10, a Potential New Treatment Option for Patients with Brain Cancer

Zealand informs that data presented on Lyxumia® support known complementary effects of this diabetes medicine in combination with basal insulin

CHAMPIX® (varenicline) is Effective and Well Tolerated Compared With Placebo in Patients With a History of Major Depressive Disorder (MDD)

Almac and Queen’s University, Belfast announce £13 million investment in Cancer Research